ImmunityBio
  • Our Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Unique Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Therapies
    • Bladder Cancer
    • Glioblastoma
    • Lynch Syndrome
    • Non-Small Cell Lung Cancer
    • Pancreatic Cancer
    • COVID-19
    • HIV
  • Our Company
    • About Us
    • Investors
    • News
    • Contact
  • Careers
  • Get Started
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
Select Page
QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle- invasive bladder cancer (NMIBC)

QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle- invasive bladder cancer (NMIBC)

Jun 15, 2022 | Bladder Cancer

QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle- invasive bladder cancer (NMIBC)

Phase 2 QUILT 88 trial of DAMP inducers combined with IL15 superagonist, N-803 and anti PDL1-t-haNK cell therapy more than doubles historical overall survival with 3rd to 6th line advanced Pancreatic Cancer

Jun 15, 2022 | Pancreatic Cancer

QUILT-88: NANT Pancreatic Cancer Vaccine in 3rd, 4th, & 5th Line Advanced Disease

QUILT-88: NANT Pancreatic Cancer Vaccine in 3rd, 4th, & 5th Line Advanced Disease

Mar 25, 2022 | Pancreatic Cancer

Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

Mar 16, 2022 | Bladder Cancer

Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)

Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)

Jun 4, 2021 | Non-Small Cell Lung Cancer

« Older Entries

Recent Posts

  • United Nations “Unveiling the Future of Intelligent Health in Africa”
  • Piper Sandler Annual Healthcare Conference
  • LUGPA 2023 Annual Meeting
  • Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
  • Bladder Cancer Advocacy Network’s (BCAN) Annual Bladder Cancer Summit for Patients and Families

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  Twitter
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2023 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'Nantkwest’, ‘haNK’, ‘taNK’, ’t-haNK’, ‘ceNK’, ‘NK-92’, ‘Living Drugs in a Bag’, ‘Nature’s First Responder’, ‘Outsmart Your Disease’, and ‘Smart Therapies for Difficult Diseases’ are trademarks or registered trademarks of Nantkwest, ImmunityBio, Inc.

Anktiva is a registered trademark of ImmunityBio, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap